CANTOS Ushers in a New Calculus of Inflammasome Targeting for Vascular Protection-and Maybe More
- PMID: 29056511
- DOI: 10.1016/j.cmet.2017.09.022
CANTOS Ushers in a New Calculus of Inflammasome Targeting for Vascular Protection-and Maybe More
Abstract
Despite overwhelming basic science linking inflammation to the pathobiology of atherothrombosis, the specific clinical evidence indicating cardiovascular benefits from anti-inflammatory pharmacotherapy has been lacking. The CANTOS trial (Ridker et al., 2017a) now provides the first largescale proof of concept that inflammasome targeting can reduce cardiovascular events-and, surprisingly, lung cancer.
Copyright © 2017 Elsevier Inc. All rights reserved.
Comment on
-
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27. N Engl J Med. 2017. PMID: 28845751 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical